



20 February 2020

ASX Announcement

## Race significantly strengthens Clinical Advisory Board

- **Leading paediatric haematology oncologist Professor Jaap-Jan Boelens appointed to Race's Clinical Advisory Board**
- **Prof Boelens has over 20 years of international experience in paediatric oncology**
- **His expertise will be instrumental to the success of the Company's 5 path strategy**

---

**20 February 2020** – Race Oncology Limited (ASX: RAC) is pleased to advise that it has considerably strengthened its Clinical Advisory Board (CAB) following the appointment of leading paediatric haematology oncologist, Prof Jaap-Jan Boelens.

Prof Boelens has over 20 years' experience with a focus on immunology, oncology and paediatrics. He is the Richard J. O'Reilly Chair in Honor of Kevin Zoltan Merszei and the Chief of Pediatric Stem Cell Transplantation and Cellular Therapies Service at the Memorial Sloan Kettering Cancer Centre in New York, USA. Prof. Boelens is one of the leading specialists in bone marrow and cord blood transplantation to treat blood diseases in children and young adults and has over 192 publications in leading medical journals.

He received his MD from the University Medical Centre (UMC) Utrecht, and a PhD in Immunology from the University of Amsterdam Academic Medical Centre, Netherlands. Following a residency in paediatrics and two fellowships in immunology and oncology at the University Medical Centre Leiden, Netherlands, Prof Boelens spent a decade developing a cord blood cell transplant program, which now represents the largest of its kind in Europe. Cord blood transplants represent a promising treatment for patients who do not have a suitable bone marrow match

Race is confident that Prof Boelens' extensive expertise in clinical paediatric haematology and oncology will prove instrumental to the success of our clinical trials program.

### **Commentary:**

**Prof Boelens stated:** "I really look forward to working with the clinical advisory board at Race on development of new, improved combination regimens based on Bisantrone for children with high-risk acute leukaemia. Not only does the drug have the promise of being more efficacious than our existing treatments, but our patients' fight against cancer might now, for the first time, not be associated with the risk of life-long heart failure as the wages of successfully conquering leukaemia."

**Professor Borje Andersson, non-executive director and chair of the CAB, said:** "It is with utmost pleasure and the highest level of enthusiasm that I welcome Jaap to the Race Oncology Clinical Advisory Board. His expertise in clinical pharmacology and immunology paired with his deep, first hand understanding of all the problems facing the paediatric oncologist will be an extremely important complement to our team's program, where the clinical trial in paediatric leukaemia will take a centre role over the next few years."

- ENDS -

### **Detailed background Jaap-Jan Boelens MD PhD:**

Professor Boelens received his MD from the University Medical Centre (UMC) Utrecht, and a PhD in Immunology from the University of Amsterdam Academic Medical Centre, both in the Netherlands. After residency in Paediatrics and two fellowships Immunology and Oncology, he built a cord blood cell transplant program at the University Medical Centre Utrecht (which later became part of the Princess Maxima Centre for Pediatric Oncology in Utrecht, Netherlands). In parallel, he built a world class immunologic and pharmacokinetics research program.

Among his most notable contributions to clinical medicine and science fields are his studies on the association between dose and timing of anti-thymoglobulin and outcome after stem cell transplantation, and his definition of a therapeutic interval for the alkylating agent Busulfan when used in pre-transplant conditioning therapy in children with a variety of different diseases, both malignant and non-malignant, genetic disorders.

His research program has capitalised on these findings and expanded into studies of the clinical association between pharmacokinetics and pharmacodynamics of nucleoside analogues (represented by the prototype agent fludarabine) with clinical outcome after cancer treatment.

Since 2018, Prof Boelens has served as Chief of the Pediatric Stem Cell Transplantation and Cellular Therapies Service at the Memorial Sloan Kettering Cancer Centre in New York, USA. Prof Boelens has served and continues to serve as member and/or chair of a number of National and International Scientific Societies, notably the Board of Directors of the Cord Blood Association (CBA), the Pediatric Organizing Committee of the American Society of Blood and Marrow Transplantation/PSIG, and as Co-Chair, Centre of International Blood and Marrow Transplant Research Working Committee on Benign Disorders.

### **About Race Oncology (RAC: ASX)**

Race Oncology (RAC) is a drug development biotech with a Phase II cancer drug called Bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Peter Molloy, Managing Director

[plmolloy@raceoncology.com](mailto:plmolloy@raceoncology.com)

Media contact:

Heidi Cuthbert

+61 411 272 366

[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

**Released through:** Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538